Qixiang Guo
Biographic Data
| ID | 10030652 |
|---|---|
| NAME | Qixiang Guo |
| GIVEN NAMES | Qixiang |
| FAMILY NAME | Guo |
| SIGNATURE | GUO Q |
| AFFILIATIONS | National Medical Products Administration |
| ORCID | 0000-0002-0794-5918 |
| VERIFIED | Yes |
| TOTAL WORKS | 1 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 1 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2024 |
| LATEST PUBLICATION YEAR | 2024 |
| H-INDEX | 0 |
Assessment of clinical benefit, cost and uptake of biosimilars versus reference biologics in immune-mediated inflammatory diseases in China
Background As China is one of the countries with the highest recorded cases of Immune-Mediated Inflammatory Diseases (IMIDs), these diseases have also emerged as a serious public health concern. Biosimilars, potentially lower-cost versions of biologics, may improve access to more affordable yet comparably effective treatments. Encouragingly, China launched its abbreviated biosimilar pathway in 2015, and since then, a large number of biosimilars h…
No prominent works on this page.
Assessment of clinical benefit, cost and uptake of biosimilars versus reference biologics in immune-mediated inflammatory diseases in China
Background As China is one of the countries with the highest recorded cases of Immune-Mediated Inflammatory Diseases (IMIDs), these diseases have also emerged as a serious public health concern. Biosimilars, potentially lower-cost versions of biologics, may improve access to more affordable yet comparably effective treatments. Encouragingly, China launched its abbreviated biosimilar pathway in 2015, and since then, a large number of biosimilars h…
Biosimilar (1 works) · Biosimilars and Bioanalytical Methods (1 works) · China (1 works) · Immune system (1 works) · Immunology (1 works) · Inflammatory Bowel Disease (1 works) · Intensive care medicine (1 works) · Internal Medicine (1 works) · Medicine (1 works) · Rheumatoid Arthritis Research and Therapies (1 works)